Janine Erler Discusses Combining Academia and Business
Janine Erler became interim CEO of NEUmiRNA Therapeutics (a biotech firm focused on transformative disease modification specifically for neurological conditions) in 2022.
Janine Erler has a 22-year+ career in cancer research and has retained her fully-tenured Professor position at the University of Copenhagen while also heading up a commercial biotech research firm. Here’s her comment on what it takes to combine both academia and business:
…Janine Erler Discusses Combining Academia and BusinessRead More »